Archive for October, 2006

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma 

This study is currently recruiting patients.
Verified by National Cancer Institute (NCI) September 2006

Sponsored by:
Burzynski Research Institute

Information provided by:
National Cancer Institute (NCI)

ClinicalTrials.gov Identifier:
NCT00003508

Purpose
RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may […]

Filed:October 12th, 2006 by lmontalvo | No Comments

Merck & Co: Zolinza becomes first approved HDAC inhibitor 

10/10/06
By Dr Benjamin Friedmann
FDA approves first-in-class Zolinza (vorinostat) for cutaneous T-cell lymphoma.
Merck & Co’s Zolinza has been approved by the FDA for cutaneous T-cell lymphoma patients who have progressive, persistent or recurrent disease on or following failure of two systemic therapies, making the oral drug the first in its class to reach the market. However, […]

Filed:October 10th, 2006 by lmontalvo | No Comments

Alfacell Completes Non-Clinical Section of Rolling NDA for Lead Anticancer Drug ONCONASE 

BLOOMFIELD, N.J.–(BUSINESS WIRE)–Oct 2, 2006 - Alfacell Corporation (NASDAQ: ACEL) today announced that the company has completed the non-clinical section of the rolling submission of a New Drug Application (NDA) in preparation for its submission to the U.S. Food and Drug Administration (FDA) for its lead anticancer compound, ONCONASE (ranpirnase). ONCONASE, first in class in […]

Filed:October 2nd, 2006 by lmontalvo | No Comments